Compass Pathways Q2 net loss $38.1M; COMP005 phase 3 TRD data expected Q4 2024

COMPASS Pathways plc

2024-Q2 EPS reported -$1110.00

Net loss of $38.1M ($0.56 per share) vs $28.3M in Q2 2023; R&D expenses rose to $29.1M.
Cash position $228.6M as of June 30, 2024; full-year 2024 operating cash burn guided $110M-$130M.
Top-line COMP005 pivotal phase 3 data in treatment-resistant depression expected Q4 2024.
Gino Santini appointed Chairman of Board effective September 3, 2024; Lori Englebert named CCO.
Phase 2 PTSD study showed sustained symptom improvement; exploring optimal path forward.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gino Santini

Chairman of the Board

CMPS · COMPASS Pathways plc

Effective: 2024-09-03
Filed: August 1, 2024, 7:59 PM ET

On July 30, 2024, the board of directors (the “Board”) of the Company appointed Gino Santini to join the Board and to serve as Chairman, effective September 3 , 2024, and designated him as a Class I director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gino Santini was appointed as Chairman of the Board at COMPASS Pathways plc.

Action: appointed
Role: Chairman of the Board

Exact text from the filing

On July 30, 2024, the board of directors (the “Board”) of the Company appointed Gino Santini to join the Board and to serve as Chairman, effective September 3 , 2024, and designated him as a Class I director.

View on SEC.gov

COMPASS Pathways plc filing history →

Source: SEC EDGAR

accession 0001628280-24-033854

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.